PDCD1 and neoplasm: The primary molecular targets for these inhibitors are the programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) checkpoints, which act as co-inhibitory signals that block anti-tumor effector T-cell responses [52].